Cullinan Oncology Inc
NASDAQ:CGEM
Cullinan Oncology Inc
Interest Income Expense
Cullinan Oncology Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Cullinan Oncology Inc
NASDAQ:CGEM
|
Interest Income Expense
$21.6m
|
CAGR 3-Years
190%
|
CAGR 5-Years
122%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$757m
|
CAGR 3-Years
35%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$563.1m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Cullinan Oncology Inc's Interest Income Expense?
Interest Income Expense
21.6m
USD
Based on the financial report for Dec 31, 2023, Cullinan Oncology Inc's Interest Income Expense amounts to 21.6m USD.
What is Cullinan Oncology Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
122%
Over the last year, the Interest Income Expense growth was 227%. The average annual Interest Income Expense growth rates for Cullinan Oncology Inc have been 190% over the past three years , 122% over the past five years .